🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Concord Biotech Limited CONCORDBIO NIFTY_SMALLNSEPHARMA

Healthcare · Biotechnology · India
https://www.concordbiotech.com
Company Profile ↓
₹1,357.40
-24.46% 1Y
Mkt Cap₹14,200.60 Cr
P/E38.22
P/B7.03
Div. Yield0.58%
52W High₹1,931.58
52W Low₹1,014.80
Book Value₹192.81
EPS (TTM)₹35.52

Company Overview

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 16.7%.

Reasonable Valuation

Trades at a P/E of 38.2, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 24.9%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.11.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,046.36 Cr (-11.3% YoY); net profit ₹260.91 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -11.3%, earnings -29.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.0%, profit CAGR 2.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.00%
1 Year:-11.31%

Compounded Profit Growth

5 Years:2.81%
1 Year:-29.80%

Stock Price Performance

1 Year:-24.46%
6 Months:+2.82%
3 Months:+30.85%
1 Month:-1.65%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 37% of range
₹1,014.80 ₹1,931.58
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)64.79 · Neutral
Price Performance
1M-1.65%
3M+30.85%
6M+2.82%
1Y-24.46%
Valuation vs Sector

P/E of 38.22 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 24.9%.
  • Generates positive free cash flow.

CONS

  • Trading 29.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
38.22
Industry PE
39.97
Forward P/E
33.05
PEG Ratio
-
Book Value
₹192.81
Price to Book
7.03
P/S
13.41
EV/EBITDA
37.48
Dividend Yield
0.58%

Growth (CAGR)

Revenue 5Y
8.00%
Profit 5Y
2.81%
Revenue (YoY)
-11.31%
Earnings (YoY)
-29.80%

Profitability & Returns

ROCE
16.70%
ROE
12.93%
ROA
11.68%
Profit Margin
24.93%
Op Margin
29.13%
Gross Margin
75.15%
EPS (Latest Qtr)
₹8.46
EPS (TTM)
₹35.52

Balance Sheet & Liquidity

Debt/Equity
0.11
Quick Ratio
5.46
Current Ratio
7.39
Debt
₹2.32 Cr
Total Assets
₹2,234.73 Cr
Current Assets
₹1,250.11 Cr
Working Capital
₹1,081.03 Cr

Ownership

Promoter Holding
72.48%
Chg in Prom Hold
-1.78%
FII / Inst Holding
12.36%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹14,200.60 Cr
Total Revenue (TTM)
₹1,046.36 Cr
EBITDA
₹419.39 Cr
Free Cash Flow
₹171.73 Cr
Operating Cash Flow
₹266.88 Cr
Shares Outstanding
₹10.46 Cr
Gross Margin
75.15%
Payout Ratio
43.18%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CONCORDBIO Concord Biotech Limited NIFTY_SMALLNSEPHARMA 1,357.40 38.22 ₹14,200.60 Cr 0.58% 16.70% 12.93% 8.00% 2.81%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 273.00 Cr195.00 Cr262.00 Cr241.00 Cr319.00 Cr216.00 Cr310.00 Cr-429.88 Cr203.99 Cr247.06 Cr277.77 Cr326.08 Cr
Cost of Revenue --------128.50 Cr45.10 Cr49.02 Cr65.73 Cr85.81 Cr
Gross Profit --------301.39 Cr158.88 Cr198.04 Cr212.03 Cr240.26 Cr
Operating Expenses 146.00 Cr123.00 Cr147.00 Cr135.00 Cr187.00 Cr135.00 Cr176.00 Cr-125.58 Cr115.26 Cr127.94 Cr131.80 Cr141.28 Cr
Operating Income 113.00 Cr59.00 Cr103.00 Cr92.00 Cr118.00 Cr68.00 Cr121.00 Cr-175.81 Cr43.62 Cr70.10 Cr80.23 Cr98.99 Cr
EBITDA 127.00 Cr72.00 Cr116.00 Cr106.00 Cr132.00 Cr81.00 Cr134.00 Cr-198.26 Cr76.57 Cr104.13 Cr104.98 Cr133.70 Cr
Interest Expense 1.00 Cr1.00 Cr1.00 Cr0000-9.55 L5.86 L5.91 L8.15 L8.40 L
Pretax Income 124.00 Cr71.00 Cr110.00 Cr103.00 Cr129.00 Cr80.00 Cr130.00 Cr-183.54 Cr58.73 Cr85.68 Cr86.16 Cr114.08 Cr
Tax Provision 32.24 Cr16.33 Cr28.60 Cr25.75 Cr33.54 Cr20.00 Cr35.10 Cr-43.16 Cr14.67 Cr22.62 Cr22.51 Cr25.61 Cr
Net Income 91.00 Cr54.00 Cr81.00 Cr78.00 Cr95.00 Cr60.00 Cr96.00 Cr-140.39 Cr44.06 Cr63.06 Cr63.64 Cr88.79 Cr
Diluted EPS 8.755.217.747.419.085.709.15-13.424.216.036.088.46

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 512.00 Cr616.00 Cr-830.63 Cr998.06 Cr1,179.82 Cr1,046.36 Cr
Cost of Revenue ---197.07 Cr241.61 Cr317.71 Cr259.99 Cr
Gross Profit ---633.57 Cr756.45 Cr862.11 Cr786.37 Cr
Operating Expenses 308.00 Cr289.00 Cr-328.82 Cr370.16 Cr398.77 Cr481.54 Cr
Operating Income 184.00 Cr299.00 Cr-304.75 Cr386.28 Cr463.35 Cr304.84 Cr
EBITDA 205.00 Cr327.00 Cr-380.56 Cr468.71 Cr549.46 Cr419.39 Cr
Interest Expense 1.00 Cr1.00 Cr-4.51 Cr2.55 Cr52.93 L28.20 L
Pretax Income 214.00 Cr313.00 Cr-322.01 Cr412.56 Cr494.55 Cr344.65 Cr
Tax Provision 44.94 Cr78.25 Cr-81.93 Cr104.46 Cr122.91 Cr85.42 Cr
Net Income 169.00 Cr235.00 Cr-240.09 Cr308.10 Cr371.64 Cr260.91 Cr
Diluted EPS 177.81247.4416.7222.9529.4535.52-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 941.00 Cr1,183.00 Cr-1,513.98 Cr1,700.71 Cr2,034.25 Cr2,234.73 Cr
Current Assets ---727.70 Cr896.23 Cr1,135.24 Cr1,250.11 Cr
Cash & Equivalents ---3.50 Cr15.14 Cr90.45 L12.19 Cr
Inventory ---212.31 Cr207.95 Cr239.67 Cr326.36 Cr
Receivables ---273.76 Cr349.61 Cr521.65 Cr460.20 Cr
Total Liabilities ---223.98 Cr174.06 Cr221.53 Cr219.59 Cr
Current Liabilities ---191.84 Cr142.16 Cr184.06 Cr169.08 Cr
Long Term Debt --31.25 Cr6.24 Cr00-
Total Debt 52.00 Cr86.00 Cr-31.55 Cr9.74 Cr2.97 Cr2.32 Cr
Total Equity 771.00 Cr1,000.00 Cr-1,290.00 Cr1,526.65 Cr1,812.72 Cr2,017.06 Cr
Shares Outstanding ---10.46 Cr10.46 Cr10.46 Cr10.46 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 155.00 Cr167.00 Cr-246.00 Cr265.47 Cr244.52 Cr266.88 Cr
Investing Cash Flow -114.00 Cr-195.00 Cr--157.95 Cr-154.61 Cr-159.99 Cr-142.72 Cr
Financing Cash Flow -43.00 Cr31.00 Cr--85.22 Cr-99.21 Cr-98.77 Cr-112.88 Cr
Capital Expenditure -156.00 Cr-205.00 Cr--145.08 Cr-85.69 Cr-111.17 Cr-95.15 Cr
Free Cash Flow -1.00 Cr-38.00 Cr-100.92 Cr179.78 Cr133.34 Cr171.73 Cr
Net Change in Cash -1.00 Cr3.00 Cr-2.83 Cr11.64 Cr-14.24 Cr11.28 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---76.3%75.8%73.1%75.2%
Operating Margin % 35.9%48.5%-36.7%38.7%39.3%29.1%
Net Margin % 33.0%38.1%-28.9%30.9%31.5%24.9%
ROE % 21.9%23.5%-18.6%20.2%20.5%12.9%
ROCE % ---23.0%24.8%25.0%14.8%

Shareholding Pattern

Insiders
72.48%
Institutions
12.36%
Public Float
44.93%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CONCORDBIO

Google News hu, 25 Jun 2026

CONCORDBIO Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9ZQ0JfTEJva1U4aFl3c201MVozWjMtNUlJb0o4TndXbjJKWVRBUVJUSWc1Wm5KVEt1Rmp4QVNqTmMyTTB0RHJzLXExNFVweHAzWlRWbHRUZ2Z4bjZhM2Rvc0pXOGxfYkkxRDZEb3ZWYmlqZnZhSjZuUFQtSkxLUQ?oc=5" target="_blan…

Google News Wed, 10 Jun 2026

Time To Worry? Analysts Just Downgraded Their Concord Biotech Limited (NSE:CONCORDBIO) Outlook - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNYVRmWVlKeXFLaUJMai1EcDZSa0hfb2dfMGx1T2d3VzVMN1hzTl9rSkVUbFZWT2lmRi12dEV4ZEVlTUpQRHloRkZRaFl2ZF9vdzl6dFlSLUZ3cng0dVlyOENwc3NWQTN5Zm1EWFJNOWdzVExZbjNIbmR5dXlwVkFNaVFXQUpUenR4SDdra2…

Google News Fri, 29 May 2026

CONCORDBIO: FY 2026 delivered solid growth, a Rs. 7.55 dividend, and a strategic acquisition, despite regulatory impacts - TradingView

<a href="https://news.google.com/rss/articles/CBMipAJBVV95cUxQbERxODBZbEMzdXJfUUdCUXNQQ2poajlIenFlMHhUeW1zYy1QY0wxWEhMbks0ZDdIVmFPTVRFSmJSeTZyMU00YXBOM1MzOEFEWGZFOHRGSkxyTUluZFhHWTdFSFVJUl9jYWQ4dGthenZuUm5jSGxUUng0MV9DWU5weDVLaHgyV3Q0TkloOV…

Google News Wed, 03 Jun 2026

Concord Biotech Limited (NSE:CONCORDBIO) Just Missed Earnings: Here's What Analysts Think Will Happen Next - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOczZIUWxGN3JHcldNN3BvcGphLXVnUWZwY0VVT2I4VlFaOF9ud0tmYVJrQTZsUi1GX3pEdnpzc3ZjbXo2dWxBOWstSFpkS19IZGkzb3NCS09UT1BhQXR6NEtLRlNhcFlib3JTc3pJR3p4TkdGc1ZUMWRJczVpYlpyUFh5NVNxam02Q3hMeW…

Google News Sat, 03 Jan 2026

Concord Biotech Ltd. Share Price Today - Concord Biotech Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxOckM5dkF5ZVhyYVhoVGN6SEVzWVZYY3NqVzR1OGNvTmJwMHRLRmhvSlQweFRpdFlSUDZiYUNOeC1NTGtvS1pQVEpVQTc4RkY1M01QUEw1LWxnZHExcEtEcENNdllIc0pDVFUtWkt2T2ZhOWhFR1RmRVB0NWdkdzBDM1lR?oc=5" target=…

Google News Wed, 21 Jan 2026

Following recent decline, Concord Biotech Limited's (NSE:CONCORDBIO) top shareholder CEO Sudhir Vaid sees holdings value drop by 7.0% - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNa0FxU0V1TmxRbVRWcXVkY3ZhdzhObllTbkxHRXlHNlhjLXY4NXZHcVRWTWpMTzZkV055eEJXRmVvUnBkU1YzSFd6V1V4R1lJblFob2pFRDdsQ3ViRzhSOUtTUHpRYUlxOFpnNkZjSWFHRS1MZHVkMXJLNk81bUxtV0EwamtJVGVRWl93V3…

CONCORDBIO — Frequently Asked Questions

What is the current share price of Concord Biotech Limited (CONCORDBIO)?

As of 2026-07-15 09:52 IST, Concord Biotech Limited (CONCORDBIO) trades at ₹1,357.40 on NSE. Its 52-week range is ₹1,014.80 to ₹1,931.58.

What is the market capitalisation of CONCORDBIO?

Concord Biotech Limited (CONCORDBIO) has a market capitalisation of ₹14,200.60 Cr on NSE.

What is the P/E ratio of CONCORDBIO?

CONCORDBIO trades at a trailing price-to-earnings (P/E) ratio of 38.22. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 7.03.

Does CONCORDBIO pay a dividend?

Concord Biotech Limited (CONCORDBIO) currently offers a dividend yield of 0.58%.

What is the return on equity (ROE) of CONCORDBIO?

CONCORDBIO has a return on equity (ROE) of 12.93%. Its return on capital employed (ROCE) is 16.70%.

Is CONCORDBIO a good stock to buy?

This page provides a data-driven analysis of Concord Biotech Limited (CONCORDBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space